liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
Klinikum Carl Gustav Carus, Germany.
Carol Davila University of Medical and Pharm, Romania.
Hospital Britanico Buenos Aires, Argentina.
Virga Jessaziekenhuis, Belgium.
Show others and affiliations
2014 (English)In: Journal of Neurology, ISSN 0340-5354, E-ISSN 1432-1459, Vol. 261, no 11, 2101-2111 p.Article in journal (Refereed) Published
Abstract [en]

Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may benefit from converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed to assess the disease course of patients converting to GA 20 mg daily from another DMT. Eligible patients had converted to GA and had received prior DMT for 3-6 months, depending on the reasons for conversion. Patients were assessed at baseline and at 6, 12, 18, and 24 months. In total, 672 patients from 148 centers worldwide were included in the analysis. Change of therapy to GA was prompted primarily by lack of efficacy (53.6 %) or intolerable adverse events (AEs; 44.8 %). Over a 24-month period, 72.7 % of patients were relapse free. Mean annual relapse rate decreased from 0.86 [95 % confidence interval (CI) 0.81-0.91] before the change to 0.32 (95 % CI 0.26-0.40; p less than 0.0001) at last observation, while the progression of disability was halted, as the Kurtzke Expanded Disability Status Scale (EDSS) scores remained stable. Patients improved significantly (p less than 0.05) on measures of fatigue, quality of life, depression, and cognition; mobility scores remained stable. The results indicate that changing RRMS patients to GA is associated with positive treatment outcomes.

Place, publisher, year, edition, pages
Springer Verlag (Germany) , 2014. Vol. 261, no 11, 2101-2111 p.
Keyword [en]
Disease-modifying therapy; Glatiramer acetate; Multiple sclerosis; RRMS
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-112822DOI: 10.1007/s00415-014-7446-0ISI: 000344808400006PubMedID: 25119836OAI: diva2:777005

Funding Agencies|Teva Pharmaceuticals Industries Ltd., Petach Tikva, Israel

Available from: 2015-01-08 Created: 2014-12-17 Last updated: 2015-04-15

Open Access in DiVA

fulltext(410 kB)116 downloads
File information
File name FULLTEXT01.pdfFile size 410 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Landtblom, Anne-Marie
By organisation
Division of NeuroscienceFaculty of Health SciencesCenter for Medical Image Science and Visualization (CMIV)Department of NeurologyDepartment of Medical Specialist in Motala
In the same journal
Journal of Neurology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 116 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 138 hits
ReferencesLink to record
Permanent link

Direct link